Qualliance Pharma: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Qualliance Pharma
Largest movements
- Cash -€19,192
down €19,192 (-18.6%), from €103,328 to €84,136
mainly Contributions, distributions and other (-€147,891) and Investment in fixed assets (net) (-€7,228)
- Receivables within one year -€6,555
down €6,555 (-13.5%), from €48,422 to €41,866
- Reserves -€61,814
down €61,814 (-84.8%), from €72,891 to €11,077
- Other debts +€17,040
up €17,040 (+21.5%), from €79,403 to €96,444
- Trade debts +€13,907
up €13,907 (+112%), from €12,472 to €26,380
- Tax, wage and social debts +€7,926
up €7,926 (+55.1%), from €14,392 to €22,318
- Gross operating margin +€17,822
up €17,822 (+18.1%), from €98,467 to €116,289
- Taxes +€3,386
up €3,386 (+17.1%), from €19,803 to €23,189
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €184,158 | €161,218 | -€22,941 | -12.5% |
| Fixed assets | 21/28 | €32,384 | €33,417 | +€1,033 | +3.2% |
| Tangible fixed assets | 22/27 | €32,384 | €33,417 | +€1,033 | +3.2% |
| Plant, machinery and equipment | 23 | €5,601 | €3,334 | -€2,267 | -40.5% |
| Furniture and vehicles | 24 | €8,017 | €6,822 | -€1,195 | -14.9% |
| Other tangible fixed assets | 26 | €18,766 | €23,261 | +€4,495 | +24.0% |
| Current assets | 29/58 | €151,775 | €127,801 | -€23,974 | -15.8% |
| Amounts receivable within one year | 40/41 | €48,422 | €41,866 | -€6,555 | -13.5% |
| Trade receivables | 40 | €48,422 | €41,866 | -€6,555 | -13.5% |
| Cash at bank and in hand | 54/58 | €103,328 | €84,136 | -€19,192 | -18.6% |
| Deferred charges and accrued income | 490/1 | €26 | €1,799 | +€1,773 | +6,940% |
| Total equity and liabilities | 10/49 | €184,158 | €161,218 | -€22,941 | -12.5% |
| Equity | 10/15 | €77,891 | €16,077 | -€61,814 | -79.4% |
| Contributions | 10/11 | €5,000 | €5,000 | = | 0.0% |
| Reserves | 13 | €72,891 | €11,077 | -€61,814 | -84.8% |
| Distributable reserves | 133 | €72,891 | €11,077 | -€61,814 | -84.8% |
| Amounts payable | 17/49 | €106,268 | €145,141 | +€38,873 | +36.6% |
| Amounts payable within one year | 42/48 | €106,268 | €145,141 | +€38,873 | +36.6% |
| Trade debts | 44 | €12,472 | €26,380 | +€13,907 | +112% |
| Suppliers | 440/4 | €12,472 | €26,380 | +€13,907 | +112% |
| Taxes, remuneration and social security | 45 | €14,392 | €22,318 | +€7,926 | +55.1% |
| Taxes | 450/3 | €14,392 | €22,318 | +€7,926 | +55.1% |
| Other amounts payable | 47/48 | €79,403 | €96,444 | +€17,040 | +21.5% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €5,733 | €6,195 | +€462 | +8.1% |
| Other operating charges | 640/8 | - | €787 | +€787 | |
| Gross operating margin | 9900 | €98,467 | €116,289 | +€17,822 | +18.1% |
| Operating profit (loss) | 9901 | €92,734 | €109,307 | +€16,572 | +17.9% |
| Financial income | 75/76B | €0 | - | -€0 | |
| Recurring financial income | 75 | €0 | - | -€0 | |
| Financial charges | 65/66B | €41 | €40 | -€0 | -0.8% |
| Recurring financial charges | 65 | €41 | €40 | -€0 | -0.8% |
| Profit (loss) for the period before taxes | 9903 | €92,693 | €109,266 | +€16,573 | +17.9% |
| Income taxes | 67/77 | €19,803 | €23,189 | +€3,386 | +17.1% |
| Profit (loss) for the period | 9904 | €72,891 | €86,077 | +€13,186 | +18.1% |
| Profit (loss) for the period to be appropriated | 9905 | €72,891 | €86,077 | +€13,186 | +18.1% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 29 October 2026 via checked.be.